ArticleEuropean heart journal2025
First myocardial infarction: risk factors, symptoms, and medical therapy.
Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.European heart journal · 2026Observational
- Association of endothelial glycocalyx degradation with post-PCI slow flow phenomenon in STEMI patients: a prospective observational study.Cardiovascular diagnosis and therapy · 2026Article
- A comparative study of quantum-inspired PSO and EA with their binary variants for heart disease classification.Scientific reports · 2026Article
- Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-IT.American journal of preventive cardiology · 2026Article
- Innovations In Artificial Intelligence-Guided Atherosclerosis Cardiovascular Imaging: From Detection to Prognosis.Current atherosclerosis reports · 2026Review
- Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022.Journal of the American Heart Association · 2026Article
- The potential of artificial intelligence in clinical trials.European journal of clinical investigation · 2026Review
- Acute Myocardial Infarction in an Intermediate-Risk Patient: Implications for Cardiovascular Risk Stratification.JACC. Case reports · 2026Article
- High-Risk Coronary Plaques and Carotid Duplex Findings in Asymptomatic Patients Undergoing Primary Prevention Assessment.Journal of cardiovascular development and disease · 2026Article
- Intensive lipid-lowering therapy-related regression of a vulnerable plaque confirmed by serial optical coherence tomography: a case report.Frontiers in cardiovascular medicine · 2026Article
- Network pharmacological analysis, Mendelian randomization analysis and animal experimental reveal the mechanism of Wenxin Granules in inhibiting heart failure after myocardial infarction: apoptosis and inflammation.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND AND
aimsDespite the implementation of clinical risk algorithms based on traditional risk factors, the global burden of atherosclerotic cardiovascular disease has continued to rise over the past decades. There are few real-world data on prevalence of both symptoms and risk factors prior to myocardial infarction (MI). This study aimed to investigate the prevalence of documented coronary artery disease risk factors, documented symptoms, physician visits, and preventive therapy uptake prior to first MI.
methodsIn this retrospective cohort study, US patients ≥18 years with a first MI [International Classification of Diseases, 10th Revision (ICD-10) definition] between 1 January 2017 and 30 September 2022 were included from the Clarivate Real-World Data Product that links electronic health records, medical claims, and pharmacy claims from 98% of government and commercial health insurance plans in the US. Prevalence of previously ICD-10 documented cardiac symptoms and standard modifiable risk factors (SMuRFs), physician visits, and use of preventive medical therapy were assessed prior to MI.
resultsThe study identified 4 657 412 patients with a first MI (2017-2022), with a median age of 70 years; 42.3% were women. Prior to MI, 50.5% of patients had no documented symptoms, 18.0% had no SMuRFs, 22.2% did not have documented physician visits, and 63.4% were not prescribed any preventive therapy. Individuals ≤60 years and men were less likely to have documented symptoms and SMuRFs, had lower frequency of primary care physician visits, used less preventive therapy, and had more frequent occurrence of ST-elevation MI than individuals >60 years and women, respectively.
conclusionsIn a large real-world dataset, half of the patients with first MI did not have documented antecedent symptoms, and approximately 1 in 5 had no previously identified SMuRFs. The majority of those who visited a physician prior to the MI with identified SMuRFs and symptoms were not using any preventive medical therapy. These findings highlight an urgent unmet need for improved tools to identify patients at risk of MI who may benefit from preventive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.